	US 11,733,232 B2
	Method for producing disease modeling non-human animal, disease modeling non-human animal, and method for screening drug and method for determining risk of disease using the same
Masaaki Murakami, Sapporo (JP); Daisuke Kamimura, Sapporo (JP); and Yasunobu Arima, Sapporo (JP)
Assigned to National University Corporation Hokkaido University, Sapporo (JP)
Appl. No. 16/490,145
Filed by National University Corporation Hokkaido University, Sapporo (JP)
PCT Filed Mar. 1, 2018, PCT No. PCT/JP2018/007901 § 371(c)(1), (2) Date Aug. 30, 2019, PCT Pub. No. WO2018/159787, PCT Pub. Date Sep. 7, 2018.
Claims priority of application No. 2017-038115 (JP), filed on Mar. 1, 2017.
Prior Publication US 2020/0049696 A1, Feb. 13, 2020
Int. Cl. G01N 33/50 (2006.01); A01K 67/027 (2006.01)

CPC G01N 33/5008 (2013.01) [A01K 67/027 (2013.01); A01K 2267/0318 (2013.01); A01K 2267/0356 (2013.01); A01K 2267/0368 (2013.01); A01K 2267/0375 (2013.01)]

14 Claims

1. A method for producing a mouse model of a disease having inflammation at a cerebral blood vessel, comprising intravenous administration of CD4-positive T-cells reactive to myelin oligodendrocyte glycoprotein (MOG) to a test mouse under chronic mental stress, leading to inflammation at a cerebral blood vessel in the brain of the test mouse,

wherein the chronic mental stress is selected from the group consisting of sleep deprivation, perpetual avoidance from water on a wheel (PAWW) stress, wet bedding, social defeat stress, and maternal separation stress.